Vepdegestrant (ARV-471) is an oral estrogen receptor PROTAC protein degrader for breast cancer. Vepdegestrant (ARV-471) is a heterobifunctional molecule that promotes the interaction between estrogen receptor alpha and intracellular E3 ligase complexes. Vepdegestrant (ARV-471) causes ubiquitination and subsequent degradation of the estrogen receptor via the proteasome. Vepdegestrant (ARV-471) potently degrades ER-positive The ER in breast cancer cell lines is potently degraded by ARV-471 with a DC50 value of approximately 2 nM.
| Molecular Weight | 723.9 |
| Formula | C45H49N5O4 |
| CAS Number | 2229711-68-4 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage | -20°C, protect from light, dry, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] Diego Garcia Jimenez, et al. ADMET DMPK. Are we ready to design oral PROTACs®?
| Related PROTAC Products |
|---|
| CPS2
CPS2 is a first-in-class, highly potent, selective, and irreversible PROTAC CDK2 degrader (IC50= 24 nM) for AML-related studies. |
| YD23
YD23 is a SMARCA2 PROTAC. |
| CST626
CST626 is a pan-IAP degrader PROTAC. |
| BacPROTAC-1
BacPROTAC-1 is a mSA BacPROTAC degrader. |
| ML 2-23
ML 2-23 is a potent PROTAC BCR-ABL degrader. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
